GGrantIndex
← Search

Development Funds

$427,352P30FY2017CANIH

Northwestern University At Chicago, Evanston IL

Investigators

Linked publications, trials & patents

Trial NCT07639528Trial NCT07594626Trial NCT07594548Trial NCT07290543Trial NCT07261657Trial NCT07178301Trial NCT07169617Trial NCT07050186Trial NCT07042919Trial NCT06959641Trial NCT06813898Trial NCT06723457Trial NCT06630416Trial NCT06571734Trial NCT06499870Trial NCT06410248Trial NCT06327477Trial NCT06247540Trial NCT06244004Trial NCT06242834Trial NCT06184750Trial NCT06164275Trial NCT06137651Trial NCT06062498Trial NCT06060587Trial NCT06022822Trial NCT05879250Trial NCT05852041Trial NCT05802186Trial NCT05744739Trial NCT05733000Trial NCT05620771Trial NCT05576896Trial NCT05545150Trial NCT05453799Trial NCT05419011Trial NCT05411107Trial NCT05236036Trial NCT05202782Trial NCT05093387Trial NCT04931017Trial NCT04910425Trial NCT04795869Trial NCT04767984Trial NCT04753216Trial NCT04576104Trial NCT04550481Trial NCT04250051Trial NCT04227028Trial NCT04200443Trial NCT04049227Trial NCT04047706Trial NCT04033432Trial NCT04009044Trial NCT03854474Trial NCT03812562Trial NCT03742258Trial NCT03723915Trial NCT03704714Trial NCT03513484Trial NCT03317405Trial NCT03278925Trial NCT03226249Trial NCT03213041Trial NCT03146650Trial NCT03077828Trial NCT03070002Trial NCT03061188Trial NCT03048500Trial NCT03044730Trial NCT03036930Trial NCT03020017Trial NCT02993159Trial NCT02968810Trial NCT02965703Trial NCT02901899Trial NCT02892734Trial NCT02871323Trial NCT02861040Trial NCT02847559Trial NCT02837029Trial NCT02819804Trial NCT02808143Trial NCT02805868Trial NCT02794883Trial NCT02774681Trial NCT02743364Trial NCT02720484Trial NCT02694809Trial NCT02536794Trial NCT02530619Trial NCT02530502Trial NCT02530125Trial NCT02481310Trial NCT02365480Trial NCT02357810Trial NCT02314156Trial NCT02242097Trial NCT02237183Trial NCT02232516

Abstract

The Cancer Control and Survivorship Program ofthe Robert H. Lurie Comprehensive Cancer Center is a multi-disciplinary program focusing on three thematic areas: (a) Measure, Analyze and Interpret Quality of Life (QOL), (b) Understand and Improve Cancer Survivorship, and (c) Symptom Management and Supportive Care. The Program Leader is Frank J. Penedo, PhD, an accomplished clinical health psychologist whose research focuses on psychosocial and biobehavioral determinants of adjustment to cancer and the efficacy of manualized interventions on QOL and health outcomes with emphasis on ethnic minorities, and the Program Co-Leader is Jamie Von Roenn, MD, a distinguished medical oncologist with expertise in palliative oncology education and research. The objective ofthe Cancer Control and Survivorship Program, which is comprised of 38 faculty members from 13 departments and 2 schools is to facilitate and focus research on secondary cancer control and survivorship within the Cancer Center. Between August 2007 and July 2012, there were 545 cancer-relevant publications from the program members, with 26.6% representing intra-programmatic and 31.4% representing inter-programmatic collaborations. A total of 7,138 participants were enrolled in program studies with 2,802 enrolled on intervention studies and 4,336 enrolled on observational or correlative studies. Total cancer relevant funding for the Program is $14,818,344, with 70% coming from peer reviewed funding. Peer reviewed funding is $10,367,715 (total) and $7,612,441 (direct), with $1,819,740 (23.9%) from NCI and $5,792,702 from other peer reviewed sources. Areas of research include: measurement science, determinants of optimal survivorship including basic mechanisms, psychosocial interventions and educational programs, and symptom palliation. The contribution of program efforts in improving quality of life, state ofthe art assessment of patient reported outcomes and palliation of cancer-related physical and psychosocial symptom burden via psychosocial interventions, coupled with community based activities, support the significance of this work. The Program is highly innovative as it involves multiple projects implementing cutting edge technology. The Program actively seeks to improve cancer control and survivorship by developing and implementing methodologically sound, clinically relevant and highly innovative research initiatives that are clinically effective and translational, aimed to reduce the burden of cancer across multiple communities. Members' interests and capabilities span many disciplines. Their integrated focus upon cancer control and survivorship promotes an environment of intra- and inter-program collaboration and productivity.

View original record on NIH RePORTER →